Global Leaders in Geroscience Convene for Biomarkers of Aging

Advancing Science Through Cross-Sector Collaboration

The Biomarkers of Aging Consortium will host its fourth annual conference on October 5 and 6, 2026, at the Joseph B. Martin Conference Center at Harvard Medical School. This gathering unites experts from academia, clinical practice, industry, regulatory agencies, and philanthropic organizations. Their shared goal is to advance the development, validation, and real-world application of biomarkers that measure biological aging.

The conference emphasizes interdisciplinary dialogue as essential for progress in geroscience. Participants will discuss recent findings on molecular, physiological, and imaging biomarkers linked to age-related decline. Sessions will focus on standardizing measurement techniques across studies and populations. Industry partners will share insights on translating discoveries into diagnostic tools and therapeutic monitoring strategies. Regulatory representatives will outline pathways for biomarker qualification in clinical trials and drug approval processes. Philanthropic funders will highlight priorities for supporting high-impact, open-access research initiatives.

How Can Biomarkers Transform Clinical Practice?

Reliable aging biomarkers could revolutionize preventive medicine by identifying individuals at elevated risk for multiple chronic conditions before symptoms appear. They may enable personalized intervention timing, such as initiating lifestyle changes or therapies based on biological rather than chronological age. In research settings, these markers could shorten trial durations by providing early signals of intervention efficacy. However, challenges remain regarding variability across individuals, ethnic groups, and environmental exposures. Speakers will address efforts to establish reference ranges and longitudinal tracking protocols. Validation in diverse cohorts is seen as critical to ensuring equitable application across global populations.

What types of biomarkers will be discussed at the conference? The event will cover a broad spectrum including epigenetic clocks, proteomic signatures, metabolic markers, senescence-associated indicators, and functional measures like gait speed and grip strength. Discussions will also include emerging technologies such as single-cell analysis and AI-driven multi-omics integration.

Frequently Asked Questions

Who is eligible to attend or participate in the Biomarkers of Aging Conference? The conference is open to researchers, clinicians, industry scientists, regulators, and funders actively involved in aging biomarker development or application. Attendance requires registration through the Biomarkers of Aging Consortium website, with options for in-person and virtual participation to accommodate global attendees.

What outcomes are expected from this year’s meeting? Organizers anticipate consensus statements on priority biomarker panels for specific use cases, such as frailty prediction or treatment response monitoring. Working groups will form to address standardization gaps and data sharing frameworks. The meeting aims to accelerate the integration of aging biomarkers into both research pipelines and healthcare systems.